Massachusetts Financial Services Co. MA Invests $242,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Massachusetts Financial Services Co. MA bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 23,662 shares of the company’s stock, valued at approximately $242,000.

Other hedge funds have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in shares of iTeos Therapeutics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after purchasing an additional 690 shares during the period. Creative Planning increased its stake in iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after buying an additional 1,196 shares during the period. nVerses Capital LLC raised its position in shares of iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after buying an additional 1,700 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of iTeos Therapeutics by 4.9% during the 1st quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after buying an additional 1,817 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of iTeos Therapeutics by 60.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after acquiring an additional 2,646 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

Insider Activity at iTeos Therapeutics

In other news, CFO Matthew Gall bought 5,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average cost of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.50% of the stock is owned by insiders.

iTeos Therapeutics Stock Up 4.3 %

Shares of iTeos Therapeutics stock opened at $8.54 on Thursday. iTeos Therapeutics, Inc. has a 12-month low of $7.54 and a 12-month high of $18.75. The firm has a market capitalization of $312.00 million, a PE ratio of -2.71 and a beta of 1.39. The stock’s fifty day moving average is $9.23 and its 200-day moving average is $13.74.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.13. Analysts expect that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wells Fargo & Company initiated coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 target price for the company. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a report on Friday, November 15th. Finally, JPMorgan Chase & Co. cut their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.